MediWound Ltd. - Ordinary Shares (MDWD): Price and Financial Metrics

MediWound Ltd. - Ordinary Shares (MDWD): $14.98

0.63 (-4.04%)

POWR Rating

Component Grades








Add MDWD to Watchlist
Sign Up

Industry: Biotech




#317 of 351

in industry

MDWD Price/Volume Stats

Current price $14.98 52-week high $19.86
Prev. close $15.61 52-week low $7.10
Day low $14.51 Volume 83,100
Day high $15.94 Avg. volume 63,326
50-day MA $17.03 Dividend yield N/A
200-day MA $12.51 Market Cap 139.07M

MDWD Stock Price Chart Interactive Chart >

MediWound Ltd. - Ordinary Shares (MDWD) Company Bio

MediWound Ltd. focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and others. The company was founded in 2000 and is based in Yavne, Israel.

MDWD Latest News Stream

Event/Time News Detail
Loading, please wait...

MDWD Latest Social Stream

Loading social stream, please wait...

View Full MDWD Social Stream

Latest MDWD News From Around the Web

Below are the latest news stories about MEDIWOUND LTD that investors may wish to consider to help them evaluate MDWD as an investment opportunity.

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound an additional $6.7 million i

Yahoo | December 28, 2023

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridementYAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with

Yahoo | December 21, 2023

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

MediWound Ltd. ( NASDAQ:MDWD ) shareholders would be excited to see that the share price has had a great month, posting...

Yahoo | December 18, 2023

Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 13, 2023

MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years ago

While not a mind-blowing move, it is good to see that the MediWound Ltd. ( NASDAQ:MDWD ) share price has gained 14% in...

Yahoo | December 5, 2023

Read More 'MDWD' Stories Here

MDWD Price Returns

1-mo -11.78%
3-mo -4.77%
6-mo 40.89%
1-year 48.02%
3-year -53.48%
5-year -40.06%
YTD 47.30%
2023 -24.61%
2022 -18.34%
2021 -36.22%
2020 19.35%
2019 -23.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!